Effect on Bronchodilation Response and Ventilation Heterogeneity of Different Inhalation Volumes in COPD

COPD Clinical Trial

— BREATH COPD  

Official title:

Effect on Bronchodilatation Response and Ventilation Heterogeneity of Different Inhalation Volumes in COPD: the BREATH COPD Study

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05381415
• Other study ID #: BREATHCOPD2022
• Status: Not yet recruiting
• Start date: June 10, 2024
• Est. completion date: July 10, 2025

Study information

• Verified date: January 2024
• Source: University of Milan
• Contact: Pierachille Santus, PhD,MD,Prof
• Phone: 0239042801
• Email: pierachille.santus[@]unimi.it
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

During bronchodilator tests, it's common to ask patients with asthma or chronic obstructive pulmonary disease (COPD) to take bronchodilator therapy by inhaling after a maximal exhalation, when the respiratory system volume equals the residual volume. The same maneuver is required for the chronic therapy.

Nevertheless, in patients with COPD the distribution of ventilation is more heterogeneous, especially when lung volumes are closer to residual volume . It is therefore predictable that the distribution of air volume containing bronchodilator that has been inhaled at residual volume is more heterogeneous than at higher volumes, such as at functional residual capacity. Accordingly, the bronchodilator can be preferentially distributed in more open airways than in less patent ones, with a heterogeneous distribution of the medication. Therefore, the overall bronchodilation should be greater when the drug inhalation is performed at functional residual capacity than at residual volume.

It is common knowledge that the effectiveness of bronchodilator therapy with pMDI in subjects with COPD is greatly affected by the inhalation technique, which can be difficult to perform for many patients. Therefore, in addition to the possibility that inhalation of bronchilation therapy at residual volume could lower the drug effectiveness, this maneuver complicates the sequence of actions required to the patient, enhancing the risk of errors and decreasing the aderence to treatment.

The aim of this study is to investigate whether the inhalation of a bronchodilator at different lung volumes can affect its effectiveness in terms of respiratory function, in patients with COPD.

Assuming that the bronchodilator effectiveness is equal or greater when inhaled at functional residual capacity rather than at residual volume, the inhalation maneuver can be simplified for patients with COPD.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 30
• Est. completion date: July 10, 2025
• Est. primary completion date: July 10, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years and older

Eligibility

Inclusion Criteria:

• age above 40 years old;

• history of smoking equal or above 10 PKYs;

• VEMS after bronchodilatation = 70%,

• medical Necessity to perform a bronchodilatation test.

Exclusion Criteria:

• history of bronchial asthma or other chronic respiratory diseases such as pulmonary fibrosis;

• uncontrolled cardiovascular diseases at the time of the visit;

• current pregnancy;

• incapacity to execute lung function tests for cognitive impairment, substance abuse or claustrophobia;

• known hypersensitivity or intolerance to salbutamol.

Related Conditions & MeSH terms

• COPD
• Lung Injury

Intervention

Other:
• Inhalation of bronchodilation therapy at FRC
the patient will be asked to inhale the bronchodilator (salbutamol pMDI, 400 µg) with a spacer from FRC (functional residual capacity, in a random order, with the assistance of an operator. The spacer will be connected to a Fleish flowmeter placed in series with the pMDI device. The valve included in the spacer will guarantee that only the air inhaled by the patient will pass through the flowmeter, reducing the risk of contamination. In both cases a low inspiratory flux and a period of apnea after inhalation of 10 seconds will be used. Before and after the administration it will be asked to the patient to execute a spirometry, a plethysmography, a lung diffusion test, and the NEP technique. These will allow the characterization of the bronchodilator effect in terms of static and dynamic volumes, heterogeneity of ventilation distribution and volume of closure, expiration flux-limitation.
• Inhalation of bronchodilation therapy at RV
the patient will be asked to inhale the bronchodilator (salbutamol pMDI, 400 µg) with a spacer from VR , with the assistance of an operator. The spacer will be connected to a Fleish flowmeter placed in series with the pMDI device. The valve included in the spacer will guarantee that only the air inhaled by the patient will pass through the flowmeter, reducing the risk of contamination. In both cases a low inspiratory flux and a period of apnea after inhalation of 10 seconds will be used. Before and after the administration it will be asked to the patient to execute a spirometry, a plethysmography, a lung diffusion test, and the NEP technique. These will allow the characterization of the bronchodilator effect in terms of static and dynamic volumes, heterogeneity of ventilation distribution and volume of closure, expiration flux-limitation.

Locations

Country	Name	City	State
Italy	L. Sacco Hospital	Milan

Sponsors (2)

Lead Sponsor	Collaborator
University of Milan	Department of Clinical and Surgical Pathophysiology and Transplantation, University of Milan

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Efficacy of bronchodilation therapy inhaled at Functional Residual Capacity (FRC) on Forced Expiratory Volume in 1 second (FEV1)	Assuming that the bronchodilator effectiveness is equal or greater when inhaled at functional residual capacity rather than at residual volume, the inhalation maneuver can be simplified for patients with COPD.	1 year
Secondary	Effects on change in phase III slope of the closing volume curve	Efficacy of bronchodilation therapy inhaled at FRC on reducing phase III slope of the closing volume, as compared to bronchodilation therapy inhaled at RV	1 year
Secondary	Effects on forced vital capacity (FVC)	Efficacy of bronchodilation therapy inhaled at FRC on static and dynamic lung volumes as compared to bronchodilation therapy inhaled at RV	1 year
Secondary	Effects on vital capacity (VC)	Efficacy of bronchodilation therapy inhaled at FRC on static and dynamic lung volumes as compared to bronchodilation therapy inhaled at RV	1 year
Secondary	Effects on residual volume (RV)	Efficacy of bronchodilation therapy inhaled at FRC on static and dynamic lung volumes as compared to bronchodilation therapy inhaled at RV	1 year
Secondary	Effects on total lung capacity (TLC)	Efficacy of bronchodilation therapy inhaled at FRC on static and dynamic lung volumes as compared to bronchodilation therapy inhaled at RV	1 year
Secondary	Effects on sensation of dyspnea as measured by modified Medical Research Council (mMRC) score	Efficacy of bronchodilation therapy at functional residual capacity on sensation of dyspnea	1 year
Secondary	Effects on specific airway resistance (sRAW)	Efficacy of bronchodilation therapy at functional residual capacity on specific pulmonary resistances	1 year